Glycopyrronium Bromide Colonis Pharma (Glycopyrronium Bromide)

Glycopyrronium bromide is employed as a bronchodilator in the management of chronic obstructive pulmonary disease (COPD) and other obstructive airway conditions.

• Maintenance therapy for COPD to improve lung function and reduce symptoms.
• Adjunct to short‑acting bronchodilators for rapid relief of episodic breathlessness.
• Considered in patients with a history of frequent COPD exacerbations to lower exacerbation risk.
• May be used in asthma management when standard inhaled therapies are unsuitable.
• Provides anticholinergic bronchodilation that helps decrease airway resistance and improve airflow.

The safety profile of glycopyrronium bromide includes both frequently observed and less common adverse reactions.

Common

• Dry mouth or reduced salivation.
• Constipation or slowed gastrointestinal motility.
• Blurred vision or difficulty focusing.
• Headache, often mild and transient.
• Cough or throat irritation.
• Urinary hesitancy without full retention.

Serious

• Paradoxical bronchospasm requiring immediate medical attention.
• Severe allergic reactions such as anaphylaxis.
• Marked tachycardia or arrhythmia.
• Acute angle‑closure glaucoma leading to visual loss.
• Significant urinary retention causing bladder distension.
• Profound constipation with risk of bowel obstruction.

When prescribing glycopyrronium bromide, clinicians should evaluate patient history and monitor for potential risks.

• Avoid use in individuals with known narrow‑angle glaucoma.
• Use cautiously in patients with existing urinary retention or prostate enlargement.
• Assess hepatic function; severe impairment may require dose adjustment.
• Elderly patients may be more susceptible to anticholinergic side effects.
• Monitor cardiovascular status, especially in patients with arrhythmias.
• Discontinue if signs of severe allergic reaction appear.
• Consider renal function; dose modification may be needed in marked renal insufficiency.

Glycopyrronium bromide can interact with other medications, influencing efficacy or safety.

Avoid

• Concurrent use of other anticholinergic agents that may amplify anticholinergic burden.
• Strong CYP3A4 inhibitors if the drug is metabolized via this pathway (e.g., ketoconazole).

Use with caution

• Beta‑agonists or other bronchodilators due to additive cardiovascular effects.
• QT‑prolonging drugs, as combined use may increase arrhythmia risk.
• Medications that can precipitate urinary retention (e.g., antihistamines, tricyclic antidepressants).
• Drugs affecting intraocular pressure in patients predisposed to glaucoma.